Home

ONCOVID Study

ONCOVID Study

COVID-19—Epidemiology of SARS-CoV-2 and mortality from COVID-19 among French cancer patients treated with hydroxychloroquine and azithromycin.

The ONCOVID study, which is recruiting more than 1,000 patients, aims to screen for the presence of the SARS-CoV-2 coronavirus in all cancer patients, whether asymptomatic or exhibiting symptoms suggestive of COVID-19, in order to measure the incidence and prevalence of the SARS-CoV-2 virus and plan for the management of any positive cases among cancer patients.

Study Objectives

The primary objective of the ONCOVID study is to determine the prevalence and incidence of SARS-CoV-2 over a 3-month period among cancer patients (Part A), as well as to evaluate the effect of treatment with HC+/-A on the mortality rate from COVID-19 among cancer patients treated with hydroxychloroquine (HC) and azithromycin (A) (Part B).

The secondary objectives are to evaluate safety, the severity of COVID-19, response to anticancer treatments, progression-free survival, cancer-related mortality, and overall survival in cancer patients infected with SARS-CoV-2. Data from Prof. Didier Raoult’s team, as well as from other Chinese research teams, have demonstrated the antiviral activity of hydroxychloroquine and azithromycin against coronaviruses; these drugs are already approved for use in other indications.

Consequently, hydroxychloroquine monotherapy will be offered to patients infected with SARS-CoV-2 as a preventive measure to reduce their viral load and prevent progression to a symptomatic form of COVID-19. The addition of azithromycin will be offered to SARS-CoV-2-positive patients exhibiting symptoms of COVID-19, both for its antiviral effect and its antibacterial effect against potential respiratory superinfections.

Study Sponsor: Gustave Roussy
Coordinating Physician: Dr. Lisa Derosa
Study Directors: Dr. Aurélien Marabelle and Prof. Laurence Zitvogel
Study Start Date: April 3, 2020

> More information